Leerink partners issued an 'outperform' rating on Teva stock, while an insider sold shares of the company.
3 reports, 2 independent
Updated Thu 00:00
No new developments lately
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink partners issued an 'outperform' rating on Teva stock, while an insider sold shares of the company.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Leerink partners
U.S. investment bank
-
Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company
Related events
- Teva's acquired product is currently undergoing review by the FDA.
- Teva Pharmaceutical Industries discussed company strategy at an event hosted by Morgan Stanley.
- Truist Financial raised its target price on Teva Pharmaceutical Industries Ltd. stock.
- The market capitalization of Teva Pharmaceutical Industries was overtaken by another entity on the Tel Aviv Stock Exchange.